Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple…
Long-term Data Confirms Kyprolis Survival Benefit in Relapsed Myeloma Patients
New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of…
